# Blog

## Automated data preparation for QSAR modeling  
[Read more](/content/blog/automated-data-for-qsar/index.html)

## End-to-End AI-Driven Design of a First-in-Class PKMYT1 PROTAC Using Chemistry42  
[Read more](/content/blog/pkmyt1-protac/index.html)

## Teaching AI the Language of Molecules: How MMAI Gym and Liquid Intelligence are Solving the “Brute Force” Crisis in Drug Discovery  
[Read more](/content/blog/mmai-liquid-ai/index.html)

## Case Study: Insilico's Transformation  
[Read more](/content/casestudy/index.html)

## Covering Patent Holes: How LEGION Uses AI to Block Competition in Chemical Space  
[Read more](/content/blog/legion/index.html)

## Science42: DORA.  
Introducing the Draft Outline Research Assistant workflow  
[Read more](/content/blog/science42-dora/index.html)

## Reinforcement Learning with Expert Human Feedback (ReLEHF) to Advance Pharmaceutical Generative AI  
[Read more](/content/blog/relehf/index.html)

## New Milestone in AI Drug Discovery: First Generative AI Drug Begins Phase II Trials with Patients  
[Read more](/content/blog/first_phase2/index.html)

## Insilico Medicine is Using Generative AI to Design New Drugs for Rare Diseases  
[Read more](/content/blog/rare-diseases/index.html)

## Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target  
[Read more](/content/blog/ipf-phase1/index.html)

## Expanding the Immuno-oncology Toolbox with an AI-discovered Target and Novel Inhibitor  
[Read more](/content/blog/immuno-oncology/index.html)

## AI for Longevity and Prosperity: Prosperity7 Leads Insilico's $35 Million Round D2 for $95 Million Total Raise  
[Read more](/content/blog/series_d_round/index.html)

## Research Collaboration Using Insilico Medicine's AI Yields New Treatment Possibilities for ALS  
[Read more](/content/treatmentals/index.html)

## Why I Left Big Pharma for AI: Insilico Medicine's Co-CEO Dr. Feng Ren  
[Read more](/content/ren_co-ceo/index.html)

## The next step in AI drug discovery: Robots  
[Read more](/content/roboticslab/index.html)

## Using AI to Fight a Pandemic: Insilico Medicine Announces Novel Preclinical Candidate for COVID-19 Treatment  
[Read more](/content/covid_pcc/index.html)

## CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World  
[Read more](http://insilico.com.tilda.ws/ai100)

## AI Accelerates Race for New Synthetic Lethality Therapeutics  
[Read more](http://insilico.com.tilda.ws/mat2a)

## Nominating Novel USP1 Small Molecule Inhibitor as a Preclinical Candidate for BRCA mutant tumors  
[Read more](http://insilico.com.tilda.ws/usp1)

## Dual-purpose therapeutic targets predicted using AI  
[Read more](/content/dual-purposetherapeutictargetspredictedusingai/index.html)

## From Start to Phase 1 in 30 Months: AI-discovered and AI-designed Anti-fibrotic Drug Enters Phase I Clinical Trial  
[Read more](/content/phase1/index.html)

## In under 40 days since announcing the partnership, Insilco Medicine and Fosun have selected preclinical candidate and initiated IND-enabling studies with an AI-discovered inhibitor of QPCTL target  
[Read more](/content/blog/pccfosun/index.html)

## Bridging Biology, Chemistry and Medicine in Drug Discovery and Development with End-to-End Artificial Intelligence: AI-discovered Novel Antifibrotic Drug Goes First-in-Human  
[Read more](/content/blog/fih/index.html)

## Insilico Medicine Initiates First-in-Human Study of AI-discovered Drug

## Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine  
Insilico discovered a Novel disease mechanism, identified a Novel target, and designed a Novel molecule validated in preclinical experiments  
[Read more](/content/blog/pcc_kidney/index.html)

## Insilico Medicine to present Chemistry42 and the end-to-end drug discovery case study at NVIDIA GTC 2021  
We are very happy to be presenting our approach to generative chemistry and the Chemistry42 platform at the NVIDIA GTC 2021 and the application of this platform which enabled the nomination of a pre-clinical candidate for a novel target for idiopathic pulmonary fibrosis (IPF) in under 18 months.  
[Read more](/content/blog/gtc21/index.html)

## A breakthrough milestone in AI-powered drug discovery reached linking biology and chemistry with AI  
AI-generated novel molecule for a novel target discovered with AI demonstrated efficacy in a broad therapeutic area and reached preclinical candidate stage in Idiopathic Pulmonary Fibrosis (IPF)